Aidoc Secures $150M from Goldman Sachs to Scale Clinical AI Solutions

Aidoc, a leading developer of foundation-model-powered clinical AI solutions, has secured a significant $150 million Series E funding round. This investment, led by Growth Equity at Goldman Sachs Alternatives and supported by General Catalyst, SoftBank Vision Fund 2, and NVentures-Nvidia's venture capital arm-brings Aidoc’s total funding to over $500 million. The company plans to use the fresh capital to scale its Clinical AI Reasoning Engine (CARE) foundation model and expand into additional clinical indications.

Why it Matters

Diagnostic errors and delays contribute to at least 400,000 deaths annually in the United States, exacerbated by rising imaging volumes, workforce shortages, and increasing clinical complexity. Aidoc’s AI-powered tools aim to address these issues by providing real-time assistance in radiology, cardiology, neurovascular, and vascular fields, with plans to expand into oncology.

Key Risks

Despite the substantial investment and growing demand for enterprise-scale clinical AI, several risks remain. The rapid deployment of AI solutions must be balanced with stringent regulatory oversight to ensure patient safety and data privacy. Additionally, the integration of AI into existing healthcare systems can face resistance from medical professionals who may be skeptical about the reliability and accuracy of these tools. Moreover, the high costs associated with developing and maintaining advanced AI models could limit their adoption in resource-constrained settings.

The Opportunity

Aidoc’s CARE foundation model received its first FDA clearance earlier this year for a comprehensive, double-digit foundation model-based triage system for clinical imaging. This milestone underscores the company's commitment to delivering robust and clinically validated solutions. Aidoc analyzes over 60 million patient cases annually and is deployed across nearly 2,000 hospitals, positioning it as a leader in the clinical AI space.

The company also developed an enterprise AI platform, Aidoc aiOS, which embeds AI directly into clinical workflows. This platform enables health systems to deploy, manage, and scale multiple FDA-cleared solutions through a centralized operating layer, facilitating seamless integration and enhancing operational efficiency.

Executive Insights

Elad Walach, co-founder and CEO of Aidoc, emphasized the company’s vision: “By 2030, every complex diagnostic decision should be supported by AI that enables earlier detection and reduces preventable error. We feel a deep responsibility to deploy CARE safely and at scale across health systems. This funding accelerates our ability to achieve these goals comprehensively.”

Market Dynamics

The growing demand for enterprise-scale clinical AI is driven by the need to improve diagnostic accuracy and efficiency in healthcare settings. Hospitals are increasingly seeking system-wide solutions that can be deployed across entire health systems, making Aidoc’s scalable and integrated approach particularly appealing.

Conclusion

Aidoc’s latest funding round not only underscores its strong market position but also highlights the growing recognition of AI's potential to transform clinical decision-making. As the company continues to scale its CARE foundation model and expand into new clinical areas, it is well-positioned to address critical healthcare challenges and improve patient outcomes.